Bain Capital Private Equity to lead a $600m Series B round in Kailera Therapeutics.

Bain Capital Private Equity, an American private investment firm, agreed to lead a $600m Series B round in Kailera Therapeutics, a clinical-stage biopharmaceutical company focused on advancing a differentiated, late-stage portfolio of next-generation therapies for the treatment of obesity, with participation from Royalty Pharma, Invus, Adage Capital Management, CPP Investments, Surveyor Capital, RTW Investments, Janus Henderson Investors, Atlas Venture, Perseverance Capital, Qatar Investment Authority, T. Rowe Price Associates, Bain Capital Life Sciences and Sirona Capital. “With an increasing global population affected by obesity and limited options for those living with higher BMIs, the need for effective treatment options has never been greater. With this funding, we will accelerate the advancement of our pipeline, including our lead program KAI-9531 that has the potential to deliver substantial weight loss for people living with obesity. We look forward to starting our global Phase 3 trials of KAI-9531 by the end of this year—marking a pivotal step in our mission to deliver therapies that empower people with obesity to transform their health and live fuller, healthier lives,” Ron Renaud, Kailera President and CEO.